Osmosis Investment Management UK Ltd Acquires New Holdings in Illumina, Inc. $ILMN

Osmosis Investment Management UK Ltd bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 5,260 shares of the life sciences company’s stock, valued at approximately $925,000.

A number of other institutional investors and hedge funds have also made changes to their positions in ILMN. Elyxium Wealth LLC purchased a new position in shares of Illumina during the 4th quarter worth approximately $25,000. TD Waterhouse Canada Inc. purchased a new position in shares of Illumina during the fourth quarter worth $26,000. Laurel Wealth Advisors LLC acquired a new stake in shares of Illumina in the fourth quarter valued at $26,000. Activest Wealth Management raised its holdings in shares of Illumina by 671.9% in the 4th quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock valued at $32,000 after buying an additional 215 shares during the period. Finally, Keating Financial Advisory Services Inc. acquired a new position in Illumina during the 2nd quarter worth about $32,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $223.22 on Tuesday. Illumina, Inc. has a 12 month low of $88.00 and a 12 month high of $223.97. The firm has a market capitalization of $33.71 billion, a P/E ratio of 41.65, a P/E/G ratio of 3.09 and a beta of 1.44. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The company’s fifty day moving average price is $189.13 and its 200 day moving average price is $153.14.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The business had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business’s revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, sell-side analysts predict that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ILMN has been the topic of several research reports. Wall Street Zen raised shares of Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. TD Cowen increased their target price on shares of Illumina from $192.00 to $210.00 and gave the stock a “hold” rating in a report on Friday, July 31st. Guggenheim boosted their price target on shares of Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Deutsche Bank Aktiengesellschaft lowered Illumina to a “hold” rating in a report on Wednesday, August 5th. Finally, Evercore restated an “outperform” rating on shares of Illumina in a report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Illumina currently has an average rating of “Hold” and a consensus target price of $188.40.

Insider Transactions at Illumina

In other Illumina news, SVP Christensen Jakob Wedel sold 1,033 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the sale, the senior vice president owned 14,023 shares in the company, valued at approximately $2,685,684.96. The trade was a 6.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 299,336 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $217.96, for a total value of $65,243,274.56. Following the completion of the sale, the director directly owned 1,409,851 shares of the company’s stock, valued at $307,291,123.96. The trade was a 17.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 2,095,958 shares of company stock worth $401,720,974 in the last three months. Corporate insiders own 2.90% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.